GLP1R and metabolic disease: Many novel therapeutics with extreme success in treating metabolic diseases are analogues of gut-derived peptide hormones, such as semaglutide, a glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonist [3, 4].